Reshaping the Lipid Science Landscape
Despite the significance of lipids for our existence, we are only scratching the surface in lipid science, leaving many open questions to the background of their high diversity and to the functions and roles of the individual species. The evolution of lipidomics is set to tackle this problem, driven by high expectations in its ability to afford new opportunities for studying lipids and defining their roles in health and disease.
New technologies are emerging to further unlock additional dimensions of lipidomes in unprecedented detail and timeframes. In conjunction with parallel developments such as dynamic real-time determinations, accurate quantification and standardization supported by unique lipidomics designed synthetic standards, and worldwide ring trial efforts, this collectively reshapes lipid science. The whole field is further advanced by the introduction of the International Lipidomics Society (ILS) flagship, fostering international community-wide coordination and communication for the creation of lipidomics specific guidelines for good scientific practice.
This webinar will present:
- Lipidomics and how it’s driving the future of medical decisions
- Advancing lipidomics procedures towards clinics
Presenter: Dr. Kim Ekroos (Founder and CEO, Lipidomics Consulting Ltd.)
Dr Kim Ekroos is the founder and CEO of Lipidomics Consulting Ltd. He received his Ph.D. degree in biology from the Technical University in Dresden, Germany, in 2003. His expertise includes high-throughput technologies for the precise assessment of lipidomes enabled by advanced mass spectrometry, automation, and software tools towards discovery of biological architectures and of diagnostic biomarkers for clinical purpose. He is one of the pioneers in the field of lipidomics, with more than 20 years of experience in the academic, industry and regulatory disciplines of lipidomics and lipid biology. His work has among others resulted in the first-ever establishment of lipidomics based lipid biomarkers in clinical diagnostics. He is a co-founder of the Lipidomics Standards Initiative (LSI) and the president of the International Lipidomics Society.
